A new dosing regimen for Kisunla, to help lower the risk of certain side effects, has been approved by the U.S. Food and Drug ...

A new dosing regimen for Kisunla, to help lower the risk of certain side effects, has been approved by the U.S. Food and Drug Administration.

Alzheimer’s Association urging ‘action now’ for awareness month June is Alzheimer’s and Brain Awareness Month, and the Alzheimer’s Association is urging patients, caregivers, and supporters to “take ...

The U.S. Food and Drug Administration (FDA) has approved monthly maintenance dosing for Leqembi (lecanemab), a treatment for early Alzheimer’s disease. “The approval of once every four-week ...

After a third review of safety data, an independent board recommended two trials of simufilam for Alzheimer's continue without modification.

Foralumab, an investigational nasal spray being developed by Tiziana Life Sciences, has been cleared by the U.S. Food and Drug Administration (FDA) for expanded use to treat moderate Alzheimer’s ...

A total of 1,929 Alzheimer's patients have enrolled in two simufilam studies, which the FDA said could support its application for approval.

The FDA has approved BrainSee, a software for predicting Alzheimer's dementia in people with mild cognitive impairments.

Many states use the Silver Alert program to track missing older adults, columnist Ray Burow writes. Read more on dementia and wandering.

Anavex is preparing meetings with regulatory authorities in the U.S., Europe, and Asia-Pacific to discuss Anavex 2-73’s potential approval.

The PrecivityAD blood test was found to influence doctors' decisions to treat for Alzheimer's disease in a real-world study.

Recruitment has begun at the first clinical site of START, a Phase 2 study evaluating Elayta in adults with early Alzheimer's disease.